113 related articles for article (PubMed ID: 19879234)
21. Inability of interferon to protect virus-infected cells against lysis by natural killer (NK) cells correlates with NK cell-mediated antiviral effects in vivo.
Bukowski JF; Welsh RM
J Immunol; 1985 Nov; 135(5):3537-41. PubMed ID: 2413125
[TBL] [Abstract][Full Text] [Related]
22. Natural cytotoxicity against mouse hepatitis virus-infected target cells. I. Correlation of cytotoxicity with virus binding to leukocytes.
Holmes KV; Welsh RM; Haspel MV
J Immunol; 1986 Feb; 136(4):1446-53. PubMed ID: 3003198
[TBL] [Abstract][Full Text] [Related]
23. Prophylactic efficacy of high-molecular-weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis.
Tripathi P; Gupta SK; Sinha S; Sundar S; Dube A; Naik S
Scand J Immunol; 2008 Nov; 68(5):492-501. PubMed ID: 18803606
[TBL] [Abstract][Full Text] [Related]
24. Toxoplasma gondii induces a T-independent IFN-gamma response in natural killer cells that requires both adherent accessory cells and tumor necrosis factor-alpha.
Sher A; Oswald IP; Hieny S; Gazzinelli RT
J Immunol; 1993 May; 150(9):3982-9. PubMed ID: 8473745
[TBL] [Abstract][Full Text] [Related]
25. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
Mazumdar T; Anam K; Ali N
Vaccine; 2004 Mar; 22(9-10):1162-71. PubMed ID: 15003644
[TBL] [Abstract][Full Text] [Related]
26. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
Bhaumik SK; Naskar K; De T
Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
[TBL] [Abstract][Full Text] [Related]
27. The role of mannose receptor during experimental leishmaniasis.
Akilov OE; Kasuboski RE; Carter CR; McDowell MA
J Leukoc Biol; 2007 May; 81(5):1188-96. PubMed ID: 17261547
[TBL] [Abstract][Full Text] [Related]
28. Leishmania donovani: evolution and architecture of the splenic cellular immune response related to control of infection.
Melby PC; Tabares A; Restrepo BI; Cardona AE; McGuff HS; Teale JM
Exp Parasitol; 2001 Sep; 99(1):17-25. PubMed ID: 11708830
[TBL] [Abstract][Full Text] [Related]
29. Early IFN-gamma production and innate immunity during Listeria monocytogenes infection in the absence of NK cells.
Andersson A; Dai WJ; Di Santo JP; Brombacher F
J Immunol; 1998 Nov; 161(10):5600-6. PubMed ID: 9820538
[TBL] [Abstract][Full Text] [Related]
30. Salmonella typhimurium induces IFN-gamma production in murine splenocytes. Role of natural killer cells and macrophages.
Ramarathinam L; Niesel DW; Klimpel GR
J Immunol; 1993 May; 150(9):3973-81. PubMed ID: 8473744
[TBL] [Abstract][Full Text] [Related]
31. Combined liposomal immuno- and chemotherapy of visceral leishmaniasis.
Everlien H; Hockertz S
Arzneimittelforschung; 1999 Nov; 49(11):954-61. PubMed ID: 10604050
[TBL] [Abstract][Full Text] [Related]
32. Parasite-accessory cell interactions in murine leishmaniasis. II. Leishmania donovani suppresses macrophage expression of class I and class II major histocompatibility complex gene products.
Reiner NE; Ng W; McMaster WR
J Immunol; 1987 Mar; 138(6):1926-32. PubMed ID: 2434567
[TBL] [Abstract][Full Text] [Related]
33. Parasite accessory cell interactions in murine leishmaniasis. I. Evasion and stimulus-dependent suppression of the macrophage interleukin 1 response by Leishmania donovani.
Reiner NE
J Immunol; 1987 Mar; 138(6):1919-25. PubMed ID: 3493291
[TBL] [Abstract][Full Text] [Related]
34. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis.
Scharton-Kersten T; Afonso LC; Wysocka M; Trinchieri G; Scott P
J Immunol; 1995 May; 154(10):5320-30. PubMed ID: 7730635
[TBL] [Abstract][Full Text] [Related]
35. Natural killer cells in mouse lung: surface phenotype, target preference, and response to local influenza virus infection.
Stein-Streilein J; Bennett M; Mann D; Kumar V
J Immunol; 1983 Dec; 131(6):2699-704. PubMed ID: 6644021
[TBL] [Abstract][Full Text] [Related]
36. IL-2-stimulated splenocytes reduce infections by Leishmania donovani in vivo.
Olivier M; Eslami Z; Tanner CE
J Parasitol; 1996 Feb; 82(1):78-81. PubMed ID: 8627506
[TBL] [Abstract][Full Text] [Related]
37. Potential of doxorubicin as an antileishmanial agent.
Sett R; Basu N; Ghosh AK; Das PK
J Parasitol; 1992 Apr; 78(2):350-4. PubMed ID: 1556650
[TBL] [Abstract][Full Text] [Related]
38. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis.
Rachamim N; Jaffe CL
J Immunol; 1993 Mar; 150(6):2322-31. PubMed ID: 8450215
[TBL] [Abstract][Full Text] [Related]
39. Hybrid cell vaccination resolves Leishmania donovani infection by eliciting a strong CD8+ cytotoxic T-lymphocyte response with concomitant suppression of interleukin-10 (IL-10) but not IL-4 or IL-13.
Basu R; Bhaumik S; Haldar AK; Naskar K; De T; Dana SK; Walden P; Roy S
Infect Immun; 2007 Dec; 75(12):5956-66. PubMed ID: 17908806
[TBL] [Abstract][Full Text] [Related]
40. Protective therapy with novel chromone derivative against Leishmania donovani infection induces Th1 response in vivo.
Mallick S; Dutta A; Ghosh J; Maiti S; Mandal AK; Banerjee R; Bandyopadhyay C; Pal C
Chemotherapy; 2011; 57(5):388-93. PubMed ID: 22024637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
